Results 131 to 140 of about 50,773 (265)

Neutrophil extracellular traps induced by activated platelets as a cause of neutrophil–platelet aggregation in β‐thalassaemia/haemoglobin E patients

British Journal of Haematology, EarlyView.
Abnormal neutrophils and platelets in splenectomised β‐thalassaemia/haemoglobin E (HbE) disease contribute to neutrophil–platelet aggregation, leading to a high risk of thrombus formation. Activated platelets induce neutrophils to generate neutrophil extracellular trap (NETs) via the P‐selectin–P‐selectin glycoprotein ligand‐1 (PSGL1) pathway, which ...
Rattanawan Thubthed, Rattanaporn Praneetponkang, Potchaman Sittipaisankul, Chayada Thiengtavor, Suwathida Chumpuchanaphai, Kittiphong Paiboonsukwong, Suthat Fucharoen, Kovit Pattanapanyasat, Jim Vadolas, Duncan R. Smith, Saovaros Svasti, Pornthip Chaichompoo   +11 more
wiley   +1 more source

Janus Kinase Inhibitor Discontinuation at a UK Tertiary Centre: A Retrospective Study. [PDF]

Cureus
Bland K, Jubber A, Ganguly S, Moorthy A.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Short-term omalizumab as a potential rescue therapy for alopecia areata flares during Janus kinase inhibitor maintenance. [PDF]

JAAD Int
Wang Q, Cheng K, Lin JM, Tao K, Xu M, Zhang X, Tang S, Ni C, Wu W, Lin J.   +9 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in Janus kinase inhibitor-experienced patients with myelofibrosis. [PDF]

J Patient Rep Outcomes
Cutts K, Cardellino A, Zhang S, Phiri K, Gelhorn H.   +4 more
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

A Successful Outcome of Upadacitinib Therapy in a Patient with Genital Erosive Fixed Drug Eruption: A Case Report

Clinical, Cosmetic and Investigational Dermatology
Changxia Li,1– 5,* Xiaobing Wang,1– 5,* Xinze Li,1– 5 Meiqin Xu,1– 5 Shuling Kong,1– 5 Xiaohua Tao,1– 5 Weijun Liu,1– 5 Haiping Wan1– 5 1Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People’s ...
Li C, Wang X, Li X, Xu M, Kong S, Tao X, Liu W, Wan H   +7 more
doaj  

Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs. [PDF]

J Vet Pharmacol Ther
Boerngen K, Patel Y, Pittorino M, Toutain CE.   +3 more
europepmc   +1 more source